Objective: Hodgkin lymphoma patients who relapsed/progressed early after autologous stem cell transplant (ASCT) usually have poor prognoses. Results from clinical trials have demonstrated Brentuximab vedotin (BV)’s significant clinical effectiveness for consolidation therapy after ASCT for patients who have high risk of relapse/progress. An economic evaluation study for Vietnamese CHL patients is necessary and can provide useful evidence for policymakers. Methods: A multi-stage economic evaluation model consisting of two partitioned survival models was used to estimate incurring costs and effectiveness from health insurance perspective for two hypothetical groups of Vietnamese adult CHL patients who have high risk of relapse/progression, one received standard care and the other received BV consolidation plus standard care as post-ASCT care. Necessary healthcare services were identified via Ministry of Health guidelines and Vietnamese clinical opinions. Efficacy parameters were taken from published systematic review and randomized controlled trials results. Model costs and utility inputs were adapted for Vietnamese context via relevant published literature, guidelines, regulations,
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً